Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.23% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.23% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -13.23% | -- | |||
| SG&A Expenses | -6.03% | -18.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.43% | -16.39% | |||
| Operating Income | 21.40% | 36.58% | |||
| Income Before Tax | 16.57% | 36.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.57% | 36.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.57% | 36.84% | |||
| EBIT | 21.40% | 36.58% | |||
| EBITDA | 21.82% | 37.05% | |||
| EPS Basic | 20.30% | 36.96% | |||
| Normalized Basic EPS | 26.62% | 36.98% | |||
| EPS Diluted | 20.30% | 36.96% | |||
| Normalized Diluted EPS | 26.62% | 36.98% | |||
| Average Basic Shares Outstanding | 4.70% | 0.18% | |||
| Average Diluted Shares Outstanding | 4.70% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||